Polyphor is a clinical stage biopharmaceutical company focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics against Gram-negative bacteria, the Outer Membrane Protein Targeting Antibiotics (OMPTA).
Products, services, technology
Balixafortide: Antagonist of CXCR4 in Phase III in patients with advanced breast cancer
Inhaled Murepavadin: Antibiotic against Pseudomonas aeruginosa in preclinical stage
POL6014 – Outlicensed to Santhera: Inhaled inhibitor of neutrophil elastase for treatment of severe lung diseases
